Insider Insights
01.11.2022
A winter of discontent? European pharmaceutical so...

EUCOPE and EFPIA have issued a joint statement expressing concerns regarding the implementation of t...

Read more
Insider Insights
18.10.2022
UK Agencies join with International HTA Partners f...

A cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can...

Read more
News
18.10.2022
PMA Insights: Week 42

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
Articles
12.10.2022
How important is HTA when launching a biosimilar i...

The short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...

Read more
Publications
28.09.2022
ISPOR 2022: Does NICE’S STA Process Effectively ...

We investigate Single Technology Appraisals (STAs) conducted by NICE, comparing outcomes for monothe...

Read more
Insider Insights
22.08.2022
MHRA awards innovation passport to a new product

The MHRA awards Innovation Passports to those products it deems innovative, in order for them to be ...

Read more
Insider Insights
22.08.2022
HAS announces changes to health evaluation

The Haute Autorité de Santé (HAS), recently announced changes to the conditions in which a drug wi...

Read more
Articles
03.08.2022
EU Joint HTA: How will EUNetHTA balance contrastin...

Our Market Access analysts summarise the EUnetHTA draft scoping process and provide considerations a...

Read more
News
14.07.2022
PMA Insights: Week 28

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
13.07.2022
Big pharmas lose out in Chinas latest round of dru

AZ has warned its China revenues will decline mid-single-digit percentage in 2022 after years of dou...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.